Plasma membrane Ca2+-ATPases in the nervous system during development and ageing

Abstract

Calcium signaling is used by neurons to control a variety of functions, including cellular differentiation, synaptic maturation, neurotransmitter release, intracellular signaling and cell death. This review focuses on one of the most important Ca²⁺ regulators in the cell, the plasma membrane Ca²⁺-ATPase (PMCA), which has a high affinity for Ca²⁺ and is widely expressed in brain. The ontogeny of PMCA isoforms, linked to specific requirements of Ca²⁺ during development of different brain areas, is addressed, as well as their function in the adult tissue. This is based on the high diversity of variants in the PMCA family in brain, which show particular kinetic differences possibly related to specific localizations and functions of the cell. Conversely, alterations in the activity of PMCAs could lead to changes in Ca²⁺ homeostasis and, consequently, to neural dysfunction. The involvement of PMCA isoforms in certain neuropathologies and in brain ageing is also discussed.

Key Words: Calcium; Brain; ATPase; Plasma membrane; Differentiation; Neurodegeneration

INTRODUCTION

Molecular systems in the plasma membrane and intracellular organelles contribute to the initiation of Ca²⁺ signals but also act as buffers for intracellular Ca²⁺ regulation. Among all systems involved, cells use Ca²⁺-ATPases as high affinity active transporters to pump Ca²⁺ ions through the plasma membrane (PMCA) or organelle membranes of sarco-endoplasmic reticulum (SERCA) and secretory pathway (SPCA). The resulting transmembrane Ca²⁺ gradients are used in a variety of signaling processes mediated by gated ion channels. PMCA shows a very high affinity for Ca²⁺ (kDa around 100 nmol/L)[1] and is directly involved in pumping Ca²⁺ out of the cell. PMCA hydrolyzes one mol of ATP in order to get the energy to transport one mol of Ca²⁺ from the cytoplasm to the extracellular media across the plasma membrane, with a Ca²⁺/H⁺ countertransport molar ratio of 1/1 and 1/0.6 for erythrocytes and brain PMCA, respectively[2,3]. This protein is about 130 kDa, contains 10 transmembrane domains and a characteristic carboxyl terminal tail responsible of the high regulation of PMCA activity, e.g. stimulation by calmodulin, phospholipids and kinases, controlled proteolysis (reviewed in[4]) and regulation by ethanol[5]. The high affinity of PMCA for calmodulin has been widely used to purify PMCA from brain[6] and cerebellum[7] and from other non-neural tissues[8], and have allowed an extensive characterization of PMCA proteins.

PMCAs belong to the P_2B branch of the P-type ATPase superfamily, characterized by the formation of a phosphorylated intermediate during the reaction cycle[9]. Four different genes have been described (ATP2B1-4) that encode four PMCA isoforms (PMCA1, 2, 3 and 4). In addition, the primary gene transcripts can be alternatively spliced in two major regions (site A, close to a phospholipid-sensitive region in the first intracellular loop, and site C, in the regulatory region in the C-terminal tail) to give over 20 variants (reviewed in[10,11]). The isoforms are widely distributed in most eukaryotic cells, although the physiological role of such abundance of PMCAs is still far from clear.

Brain is the region with the highest quantity and diversity of PMCA isoforms, which must be related to the involvement of Ca²⁺ in many neuronal functions. Rest Ca²⁺ levels in neuronal cells increase from nmol/L to μmol/L range to activate a spectrum of cellular events, from synaptic transmission to neuronal plasticity, intracellular signaling, neurosecretion or gene expression[12]. Afterward, intracellular Ca²⁺ must be restored quickly to resting levels to avoid cell damage and PMCAs are one of the major transporters involved in Ca²⁺ clearance. This review will focus on the distribution and function of PMCAs in Ca²⁺ homeostasis and signaling in the central nervous system, from neural development to mature brain, as well as their involvement in neuropathologies and ageing.

PMCAs AND NEURAL DEVELOPMENT

Neuronal development is characterized by a sequence of events such as cell differentiation, migration, neurite outgrowth and synaptogenesis. Ca²⁺ signaling plays a central role in the organization and regulation of these events[13,14]. In these processes, PMCAs are considered major players for Ca²⁺ homeostasis. Independently of a prenatal or postnatal brain development, an upregulation of PMCA activity has been observed from the first developing stages on[15,16]. Moreover, the major increase of PMCA activity mostly occurs during the period of greatest synaptic development, when an increase in the content of several PMCAs activators, such as calmodulin, phosphatidylserine and protein kinase C, also occurs[17-19].

Although all PMCA isoforms are present in the adult brain, not all isoforms are expressed at the same time. In fact, maturation of brain is accompanied by changes of the expression and distribution of PMCA isoforms. This has been shown at mRNA[20,21], and protein levels[16,22,23]. The PMCA1b is early expressed, although it slowly decreases as PMCA1a expression increases with the development associated with synaptic maturation. The PMCA2 appears much later, and increases particularly in cerebellum. PMCA3 differs among species, being almost constitutively expressed during chick cerebellar development[22] and generally upregulated in rodents[16,20]. By contrast, there is a low expression of PMCA4 throughout development, and a high expression in adult nervous tissue[5,24-26]. The analysis of tissue sections confirms that all isoforms are associated with developing synaptic-enriched areas[7,15,22,27]. This suggests an involvement in synaptogenesis and maturation of neuronal electrophysiological properties, where the regulation of the magnitude and duration of Ca²⁺ spikes are critically required. In spite of this isoform coexpression in brain synaptic areas, cerebellum is the region with a more specific isoform-distribution pattern, different among species. In developing chick, PMCAs 1 and 3 has a restricted distribution in the soma and dendritic trunk of Purkinje cells, evolving according with cell maturation[22], while in mice these isoforms are more concentrated in the neuropil of the molecular layer from the first postnatal week[16]. However, PMCA2 is broadly and largely detected at the plasma membrane of the body cell and the whole dendritic arborization of Purkinje cells[16,22] (Figure 1). Therefore, these cells contain the highest diversity of PMCA isoforms since their morphogenesis. This fact points out at specific compartmental Ca²⁺ regulation, since Purkinje cells are also enriched in other Ca²⁺-binding proteins such as calbindin and parvalbumin[28] and also in other Ca²⁺ pumps, such as the endoplasmic reticulum localized-SERCA2[7,15,29] and the Golgi localized-SPCA1[30,31]. Other neural cell types seem to contain a specific combination of isoforms, e.g. chick cerebellar interneurons contain PMCAs 1 and 3, and granule cells only express PMCA2 at the latest developmental stages[22]. On the other hand, both in situ hybridization and immunocytochemical studies had failed to localize any of PMCA isoforms in glial cells of rat brain sections[32,33]. However, astrocytes in primary cultures showed expression of PMCA1 and PMCA4 at comparable levels to those seen in neurons, while PMCA2 was less abundant and PMCA3 was not found[34]. This discrepancy between tissue and cultured glia is still not solved.

Figure 1 Localization of plasma membrane Ca²⁺-ATPase 2 in Purkinje cells from different species. Immunohistochemistry staining using an anti-plasma membrane Ca²⁺-ATPase 2 (PMCA2) antibody in para-sagittal sections of mature cerebella from chick, mouse, pig and human. PMCA2 is located at the plasma membrane of the soma (arrows) and in the dendritic arborization (arrowheads) of Purkinje cells. ml: Molecular layer; Pcl: Purkinje cell layer; gl: Granule layer. Scale bar: 40 μm.

The active participation of PMCAs in neural development has been also evidenced in differentiated PC12 cells containing a transient suppression of PMCA2 and 3, which in a slowing of neurite extension and survival reduction[35]. In contrast, similar suppression in stable-transfected undifferentiated PC12 induced a neuritogenesis-like process and an increase of PMCA4 when PMCA2 was blocked[36]. This suggests that a compensatory function among isoforms is possible under certain conditions.

PMCAs IN NEURAL FUNCTION

The high diversity of PMCAs in the brain and their overlapping localization in some brain areas does not imply functional redundancy, since isoforms show specific kinetic and regulatory differences. In fact, it has been reported a different rate of activation by Ca²⁺ of PMCA isoforms, PMCA3f and PMCA2a being the fastest ones, while PMCA4b is the slowest; on the other hand, alternative splicing at site C directly affects the calmodulin affinity, PMCA2b having the highest affinities (kDa around 2 nmol/L), followed by PMCA2a and 4b (5-10 nmol/L), and PMCA4a (50 nmol/L)[37]. Thus, diverse functional cell types or even distinct subcellular areas in the cell may use different PMCAs. Recent studies suggest that PMCA isoforms can be integrated in multiprotein complexes in membrane subdomains e.g. cholesterol-rich lipid rafts[38], which are emerging as important domains in cell Ca²⁺ signaling. In fact, we found that PMCA4, but not the other isoforms, is associated with lipid rafts isolated from synaptosomal plasma membranes[39]. On the other hand, lipid rafts prepared from the entire plasma membrane of primary cultured neurons contain all four PMCA isoforms and its activator calmodulin[40]. The discrepancy between both studies may be attributed to differences in the methodology and/or the existence of differences in the composition of rafts isolated from specific subcellular areas. The presence of PMCAs in rafts supports an active role of certain isoforms in cell signaling by facilitating their interaction with scaffolding proteins, such as some proteins from the membrane-associated guanylate kinase family (e.g. calcium/calmodulin-dependent serine protein kinase)[41], located at brain synapses, that interacts with PMCA4b or the Homer family [e.g. Ania-3[42], that couples N-methyl-D-aspartic acid (NMDA) and metabotropic glutamate receptors and could recruit PMCAs to domains close to Ca²⁺ influx channels]. Recently, it has been also reported an association of rat synaptosomal PMCA with tubulin, the main constituent of microtubules. This interaction resulted in the inhibition of PMCA, which can be reversed by calmodulin or ethanol[43]. Overall, the association of PMCA with different neural proteins may play a key control in neuronal Ca²⁺ signaling and regulation of synaptic activity.

Synapses can differ markedly in their efficacy and dynamics, in part due to differences in Ca²⁺ regulation. In this respect, the isoform PMCA2 has been particularly characterized since there is a restricted localization of variant PMCA2a in inhibitory presynaptic terminals throughout the adult rat brain[44], although a postsynaptic expression has also been observed in dendritic spines of cerebellar Purkinje cells[45]. Besides, PMCA2a shows a fast Ca²⁺ activation kinetics and high V_max, being particularly suitable for the rapid clearance of Ca²⁺. This suggests that the isoform may play an important role in the control of local Ca²⁺ dynamics: this may be achieved by interacting - via its PDZ domain - with the post-synaptic PSD95 proteins and the NMDA glutamate receptor at the post-synapse, and with the soluble N-ethylmoleimide-sensitive fusion protein attachment protein receptors member syntaxin-1A at the pre-synapse[46]. The PMCA localization at the presynaptic terminal, clustered in the active zones[1], and its high Ca²⁺ affinity would allow to keep low Ca²⁺ levels, thereby controlling vesicular release following neural activity.

The function of PMCAs in brain is not only associated with neural activity. The pumps are also found in the choroid plexus, an epithelial tissue involved in the production and secretion of cerebrospinal fluid. All isoforms are expressed in developing chick[22] and mouse[21], although the PMCA3 seems to be most abundant in adult tissue[27,32,33]. This isoform could play a role in the transport required for tight regulation of Ca²⁺ in the cerebrospinal fluid[47].

PMCAs, NEURAL DYSFUNCTIONS AND BRAIN AGEING

The experimental use of animal models has already allowed a great progress correlating certain pathologies to the three types of Ca²⁺ pumps. Besides, several mutations of SERCA and SPCA result directly in human disorders such as Darier and Brody diseases for SERCA[48,49] and Hailey-Hailey diseases for SPCA[50,51]. However, only one human disease with genetic origin has been linked to PMCA defects, i.e. the PMCA2-attibuted hereditary deafness[52,53]. This has been found after observation of this dysfunction in a PMCA2 knockout mouse[54] and a defective mutant mouse named deafwaddler[55]. These mice presented for first time hearing problems and balance defects related to both abnormalities in Purkinje neurons[56] and the absence of calcium carbonate crystals in the otoconia of inner ear[54], another region largely enriched in PMCA2[57]. Interestingly, PMCA2 deficiency could not be rescued by the other isoforms.

Age-dependent alterations in intracellular Ca²⁺ are the leading causes of neurodegeneration and cell death. Consequently, Ca²⁺ regulating systems could be affected by age. In fact, the activity of synaptic PMCAs decreases during aging[58,59], with a parallel reduction of calmodulin[58]. These observations support the idea that PMCA function is linked to the levels of their modulators during development (as mentioned above) as well as during ageing. Changes in PMCA function may induce increased levels of intraneuronal Ca²⁺ and/or longer time periods of Ca²⁺ elevation following stimulation, which can enhance vulnerability of aged neurons to degeneration in situations of brain stress, such as hypoxia or ischemia. In fact, a decrease of PMCA protein level has also been observed in several brain regions of gerbils subjected to forebrain ischemia followed by prolonged reperfusion[60].

We have recently reported a putative role of PMCAs in human neurodegeneration caused in Alzheimer’s disease[24], a pathology directly related to ageing and hallmarked by accumulation of plaques of amyloid beta peptide and aberrant filaments of tau, presenilin mutations, and impairment of intracellular Ca²⁺ signaling in neurons[61-64]. By performing kinetic assays, we found a specific alteration of PMCA activity with respect to Ca²⁺-dependence in membranes of human brains affected by Alzheimer’s disease. This alteration may be caused by the enrichment of toxic amyloid beta in Alzheimer’s disease brain, because similar experiments, performed in the pig animal model, show an inhibition of synaptosomal PMCA activity by the peptide, at specific Ca²⁺ concentrations. Furthermore, the amyloid beta-mediated neurotoxicity is PMCA-isoform dependent and the toxic effect can be prevented by cholesterol[24]. Although the mechanism of amyloid-beta toxicity is still far from clear, the generation of reactive oxygen species (ROS) is also believed to occur. In this respect, oxidative stress is implicated in neuronal injury by modification of intracellular Ca²⁺ levels, and then Ca²⁺-regulatory proteins could act as targets for neurotoxic ROS. In vitro studies have shown that exposure of hippocampal neurons to hydrogen peroxide results in downregulation of PMCA protein[65]. Moreover, the activity of PMCA from synaptosomes is inhibited after exposure to ascorbate/iron-induced stress[66], by peroxyl radicals, hydrogen peroxide, and peroxynitrite[67]. Similar reduction of PMCA activity is shown in membranes from aged rats[67], where oxidative modification of PMCA can be a result of age-related chronic oxidative stress.

A relationship between other neurodegenerative disorders and PMCAs has been also reported, e.g. a downregulation of PMCA2 has been described in a screen for transcriptional dysfunctions in brains affected by Huntington’s disease in both mouse models and humans[68]. Thus, differences in PMCA2 expression may induce neuronal dysfunction by alteration of the homeostasis of Ca²⁺, which is widely considered to be an important factor in the pathogenesis of a number of neurodegenerative diseases.

Concerning the involvement of altered PMCAs in neural diseases, functional approaches have showed that the synaptosomal PMCA can interact with several drugs. This is the case of phenothiazine derivatives, such as thioridazine, chlorpromazine, and fluphenazine, which have been used in the treatment of schizophrenia and psychosis. These drugs interfere with the functioning of the synaptosomal PMCA, resulting a potent inhibitor of the ATPase activity while, under some conditions (i.e. in the presence of phosphate), it increases the rate of Ca²⁺ accumulation into synaptic plasma membrane vesicles[69]. This effect has been explained by the presence of an additional step in the catalytic cycle known as slippage pathway, which involves the release of bound Ca²⁺ from the phosphorylated intermediate to the cytoplasmic side of the membrane before its transport out of the cell. This pathway had been already observed in SERCA using chlorpromazine[70] or curcumine[71]. The slippage results in ATP hydrolysis uncoupled from Ca²⁺ transport, which favors heat production in mammals in physiological conditions, but appears to be a significant mechanism of organ dysfunction in disease conditions, such as ageing or ischemia[72].

The ethanol is another drug that significantly affects the central nervous system and produces stimulation or inhibition of synaptosomal PMCA activity in a dose-dependent manner. The stimulatory effect seems to involve its direct binding to a second autoinhibitory domain next to the calmodulin binding domain[5]. The sensitivity of synaptosomal PMCA (which is enriched in PMCA4) to ethanol is similar to that found for the erythrocyte PMCA4[73]. Accordingly, ethanol ingestion may overstimulate the PMCA activity, severely affecting the synaptic transmission.

Interaction networks emerging from these observations point out the role of PMCAs as potential targets of an increasing number of drugs acting upon the central nervous system.

CONCLUSION

There are many pieces of evidence suggesting that PMCAs play a key role in the nervous system. We begin to understand their role in neural Ca²⁺ homeostasis from neural development to mature brain, and also their involvement in neurological disorders. A more comprehensive understanding of the physiological function of the large diversity of PMCA isoforms in different areas of the cell, and in particular cell types, will be crucial for the future design of effective therapies for neurological diseases.